• Maryam Rahman, Lauren L Donnangelo, Dan Neal, Kiran Mogali, Matthew Decker, and Mustafa M Ahmed.
• Department of Neurological Surgery, University of Florida, Gainesville, Florida, USA. Electronic address: mrahman@ufl.edu.
• World Neurosurg. 2015 Jul 1;84(1):41-7.

ObjectiveTo evaluate the safety of continuing acetyl salicylic acid (ASA) in patients undergoing brain tumor resection. Many patients are on antiplatelet agents that are withheld before elective neurosurgical procedures to reduce bleeding risk. Cessation of ASA in patients with cardiovascular disease is associated with a known increased risk of thrombotic events, especially in patients with coronary stents.MethodsThe medical records of patients who underwent surgical resection of a brain tumor at the University of Florida from 2010 to 2014 were evaluated. The patients were separated into groups based on preoperative ASA use and whether or not it was stopped before surgery. Patients were evaluated for thrombotic complications, postoperative hemorrhage, estimated blood loss, length of hospital stay, and discharge disposition.ResultsOf the 452 patients analyzed, 368 patients were not on chronic ASA therapy, 55 patients had their ASA discontinued before surgery, and 28 patients were continued on ASA perioperatively. The patients on preoperative ASA were comparable on all collected demographic variables. There were no statistical differences detected between the groups for outcomes including bleeding complications, need for reoperation, or thrombotic complications.ConclusionsIn this analysis, perioperative low dose ASA use was not associated with increased risk of perioperative complications.Copyright © 2015 Elsevier Inc. All rights reserved.

43 keywords...

hide…